CYP4F12: Potential Drug Targets and Biomarkers (G66002)

Target Name: CYP4F12

NCBI ID: G66002

CYP4F12

CYP4F12: Potential Drug Targets and Biomarkers

CYP4F12 (F22329_1), also known as CYP4F12A or CYP4F12B, is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the CYP4 family of proteins, which are involved in the transport and metabolism of a wide variety of drugs. CYP4F12 is a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

The CYP4F12 protein is composed of 165 amino acid residues and has a calculated molecular weight of 19.1 kDa. It is expressed in a variety of tissues, including the brain, where it is highly expressed in the cerebral cortical cortical layer. CYP4F12 is also expressed in the heart, where it is found in the cardiac muscle and in the heart failure. Additionally, it is expressed in the liver and kidneys, where it is involved in the detoxification of drugs.

CYP4F12 is involved in several physiological processes in the body, including drug transport, metabolism, and signaling. It is a high-affinity protein, which means that it has a strong affinity for a specific ligand, such as a drug molecule. This allows it to transport drugs across cell membranes and to participate in the metabolism of drugs by the liver and other organs. CYP4F12 is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the development and maintenance of tissues, and is a potential target for drugs that are used to treat diseases such as cancer and neurodegenerative diseases.

CYP4F12 has also been shown to be involved in several diseases, including cancer. For example, studies have shown that high levels of CYP4F12 are associated with poor prognosis in patients with pancreatic cancer, a highly aggressive form of cancer. Additionally, CYP4F12 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that individuals with certain genetic variations in the CYP4F12 gene are at increased risk of developing these conditions.

CYP4F12 has also been shown to be involved in cardiovascular diseases. Studies have shown that individuals with certain genetic variations in the CYP4F12 gene are at increased risk of developing cardiovascular disease, including heart failure and stroke. Additionally, CYP4F12 has been shown to be involved in the regulation of cellular signaling pathways that are involved in cardiovascular disease, such as the angiotensin II pathway. This pathway is involved in the regulation of blood pressure and has been implicated in the development of cardiovascular disease.

In conclusion, CYP4F12 is a protein that is involved in several physiological processes in the body, including drug transport, metabolism, and signaling. It is also involved in the development and maintenance of tissues, including the brain and heart, and has been shown to be involved in the regulation of cellular signaling pathways that are involved in several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. As a potential drug target or biomarker, CYP4F12 is a promising target for the development of new treatments for these diseases. Further research is needed to fully understand the role of CYP4F12 in disease and to develop effective treatments.

Protein Name: Cytochrome P450 Family 4 Subfamily F Member 12

Functions: A cytochrome P450 monooxygenase involved in the metabolism of endogenous polyunsaturated fatty acids (PUFAs). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Catalyzes the hydroxylation of carbon hydrogen bonds, with preference for omega-2 position. Metabolizes (5Z,8Z,11Z,14Z)-eicosatetraenoic acid (arachidonate) toward 18-hydroxy arachidonate (PubMed:11162607). Catalyzes the epoxidation of double bonds of PUFAs such as docosapentaenoic and docosahexaenoic acids (PubMed:16112640). Has low omega-hydroxylase activity toward leukotriene B4 and arachidonate (PubMed:11162645). Involved in the metabolism of xenobiotics. Catalyzes the hydroxylation of the antihistamine drug ebastine (PubMed:11162645)

The "CYP4F12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP4F12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets